Olanzapine
NDC Package 50090-5102-0

11-digit billing NDC: 50090510200

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Olanzapine is oral olanzapine is indicated for the treatment of schizophrenia. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-5102 and is authorized under FDA application ANDA076255.

Identification & Billing

NDC Package Code
50090-5102-0
Package Description
33 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED in 1 BLISTER PACK
Product Code
11-Digit Billing Format
50090510200
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Olanzapine
Dosage Form
-
Usage Information
Oral olanzapine is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies (14.1)].  When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks  when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see  Warnings and Precautions (5.5)]. 

Regulatory & Marketing

Labeler Name
A-s Medication Solutions
FDA Application #
ANDA076255
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-10-2013
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50090-5102-0 identifies a specific commercial package of 33 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack of Olanzapine, labeled by A-s Medication Solutions. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by A-s Medication Solutions on December 10, 2013. The current certification is valid through December 31, 2022.

How is this A-s Medication Solutions product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090510200. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
50090-5102-0
11-Digit CMS (5-4-2)
50090-5102-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.